Nonpreferred products and corresponding preferred alternatives

Beginning January 1, 2020, patients using nonpreferred products with a high patient cost share are now contacted about the availability of lower patient cost share preferred alternatives. If the patient is interested in switching, we will call or fax their provider who can determine whether the preferred alternative is clinically appropriate. This is strictly informational and not a substitute for physician‑directed medical evaluations or treatments.

 

Open the attachment to view the list of included nonpreferred products and corresponding preferred alternatives. 

      

                                                                                                                                                507643MUPENMUB